Todos Medical Ltd. announced that its CLIA/CAP-certified clinical laboratory Provista Diagnostics has filed an Emergency Use Authorization (EUA) application with the US Food & Drug Administration (FDA) for its PCR MonkeyPox Test. The EUA application was submitted for lesion-based PCR. The sensitivity achieved for the currently available lesion-based laboratory-developed test (LDT) is 0.95 viral copies per reaction (0.095 copies/ul).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% |
|
0.00% | -99.50% |
1st Jan change | Capi. | |
---|---|---|
-99.50% | 3.32K | |
-44.08% | 7.63B | |
+8.98% | 3.61B | |
+3.94% | 2.36B | |
-24.94% | 1.86B | |
-17.38% | 1.74B | |
+4.89% | 913M | |
+21.75% | 763M | |
-11.57% | 678M | |
-30.82% | 500M |
- Stock Market
- Equities
- TOMDF Stock
- News Todos Medical Ltd.
- Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for Monkeypox PCR Test to US FDA